Category: Uncategorized

FDA Investigators do not spend the entire inspection with your Quality Director. At some point, they walk the floor. They talk to line operators, lab technicians, warehouse staff, and QC analysts – people who did not attend the opening meeting, who have not been rehearsed on how to handle an inspection, and who are going to answer questions the only way they know how. Honestly.

That is not a criticism of your employees. It is a description of exactly what FDA is counting on.

I spent 14 years as an FDA Investigator and issued more Form 483s than I care to count. For the 13 years afterward, including part of the team that navigated J&J out of consent decree, I was directly responsible for FDA 483s received. I know the six questions that reveal the gap between what your SOPs say and what your employees actually do faster than anything else. I asked them myself for 14 years.

The Questions Are Not Random

The questions Investigators ask floor staff are deliberate, specific, and designed to surface one thing: whether the quality system that exists in your documentation also exists in the heads and hands of the people executing it every day.

A quality system that lives only in documents is not a quality system. It is a library. And FDA does not inspect libraries. They inspect operations.

The tone when these questions are asked is almost always conversational. Calm. Friendly, even. That is intentional. A relaxed employee answers more freely than a nervous one. And a free answer – one that has not been carefully constructed by a quality manager – is exactly what the Investigator is looking for.

What the Wrong Answer Costs You

The wrong answer does not just create an awkward moment on the floor. It hands the Investigator a thread they will pull for the rest of the inspection. A single employee who cannot describe their escalation pathway, who is vague about data integrity controls, or who hesitates in a way that suggests they have been coached on what to say rather than trained on what to know – that employee has just told the Investigator where to look next.

The facilities that answer these questions well are not the ones that spent the week before the inspection coaching their floor staff on what to say. They are the ones where training is role-specific, current, and regularly reinforced. Where deviation reporting is encouraged rather than discouraged. Where the right behaviors happen on a random Wednesday because that is simply how things work here – not because an Investigator is watching.

That kind of operation does not get built in a week. But the gaps in your current operation can be identified and addressed before FDA identifies them for you. That is the difference between a 483 observation and a clean inspection.

---

The six questions Investigators ask floor staff – the exact language used, what a strong answer sounds like, what a weak answer signals, and the specific 483 observations each question is designed to surface – are detailed in the full article on The Investigator’s Lens.

Link: https://open.substack.com/pub/devaughnedwards/p/1d2?r=7sflcx&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

Questions about your facility’s inspection readiness: devaughn@fdaid.org | fdaid.org

©FDAID LLC 2026

Most companies spend months preparing their documents for an FDA inspection. The reality is that the Investigator has already formed an opinion about your facility before your document coordinator brings out the first record.

I spent 14 years as an FDA Investigator and issued more Form 483s than I care to count. For the 13 years afterward, I was directly responsible for FDA 483s received at multiple companies. Here is something the industry does not talk about enough: the inspection does not start when the Investigator sits down and asks for your batch records. It starts the moment we pull into your parking lot. Sometimes earlier – the night before, reviewing your establishment inspection history, your prior 483 observations, and every Warning Letter your site or your parent company has ever received.

By the time you hand us a document, we already have a working theory about your facility. What happens for the rest of the inspection, in many respects, is testing that theory.

What Investigators Are Actually Watching

There are seven specific things every experienced Investigator notices before a single document changes hands – moments during the walkthrough, the opening meeting, and even the parking lot approach that set the tone for everything that follows. None of them show up in your document control system. None of them are improved by spending the week before an inspection pulling records and checking completeness.

What they reflect is the actual operating condition of your quality culture – the day-to-day reality of how your facility is managed when FDA is not watching. That is the point. Investigators are not trying to catch you in a bad moment. They are trying to determine whether the good moments are the norm or the performance.

Why This Matters More Than Most QA Teams Realize

The facilities that do well in FDA inspections are not the ones that prepare hardest in the two weeks before an Investigator arrives. They are the ones where the parking lot is maintained because someone cares about maintenance, where the floor staff compose themselves during a walkthrough because training happened last month and not last year, and where the quality director can speak fluently about an open CAPA because the real state of the quality system is something they are willing to stand behind.

That kind of facility takes years to build. It cannot be staged. And it is exactly what an Investigator is evaluating before they ever ask for a record.

---

The complete list of seven observations – including the specific behavioral and physical signals Investigators are trained to notice, and the corrective actions that change what an Investigator concludes before the formal inspection even begins – is available to paid subscribers of The Investigator’s Lens.

Link: https://devaughnedwards.substack.com/p/221?r=7sflcx

Questions about your facility’s inspection readiness: devaughn@fdaid.org | fdaid.org

©FDAID LLC 2026

Most pharmaceutical companies prepare for FDA inspections by preparing their documents. That is the wrong starting point – and experienced Investigators know it the moment they arrive.

Here is something the pharmaceutical industry does not talk about enough: an FDA inspection does not begin when the Investigator sits down and requests your batch records.

It begins before that. Sometimes well before that.

By the time your quality director says good morning, the Investigator has already observed things about your facility that are shaping how the rest of the inspection will unfold. None of those things are in your document control system. None of them will be improved by spending the week before an audit pulling records.

I spent 14 years as an FDA Investigator and issued more Form 483s than I care to count. For the 13 years afterwards, I was directly responsible for FDA 483s received at multiple companies. What I know – from both sides of that table – is that the companies that struggle in inspections are almost never undone by their documents. They are undone by things they never thought to prepare for.

The full list of what Investigators notice – and what it signals about your quality culture before a single document changes hands – is published on The Investigator’s Lens. It is the kind of insider knowledge that does not appear in any FDA guidance document, because it was never written down. It was learned.

Is Your Facility Ready for an Unannounced FDA Inspection – Today? Inspection readiness is not a document exercise. FD-AID LLC conducts mock FDA inspections and pre-inspection assessments grounded in 14 years of real investigator experience. Most gaps are found and fixed before FDA finds them – if you look in the right places. Contact devaughn@fdaid.org to schedule a pre-inspection readiness assessment.

Read the full article – seven specific things FDA Investigators notice before they touch a single document, and what each one tells them about your facility:

The Investigator’s Lens: https://devaughnedwards.substack.com/p/221

DeVaughn Edwards is a former FDA Investigator with 14 years of federal service and 13 years as a pharmaceutical quality executive. He is the founder and Principal Consultant of FD-AID LLC (fdaid.org).

devaughn@fdaid.org | devaughn@gmail.com

Copyright FDAID LLC 2026

When the same pharmaceutical manufacturer receives multiple FDA enforcement actions across multiple facilities in just a few years, it stops being a compliance problem. It becomes a pattern. And patterns tell you something about culture that no corrective action plan can paper over.

One of the largest generic drug suppliers to the U.S. market is back in FDA’s crosshairs. Again.

CDER issued a Warning Letter in March 2026 following an inspection that uncovered serious cGMP violations – including a data integrity finding that should alarm every quality professional and procurement team that sources from contract manufacturers.

This is not the company’s first Warning Letter. It is not their second. The enforcement history here goes back years, spans multiple facilities, and includes some of the most egregious documentation failures FDA has made public in recent memory.

The problem with the U.S. generics supply chain is not theoretical. It shows up in drug shortages. It shows up in recalled products. And it shows up in Warning Letters like this one – where the same quality culture failures keep producing the same regulatory outcomes at different sites of the same company.

What FDA found this time – and what it means for companies that source from manufacturers with enforcement history – is detailed in the full analysis on The Investigator’s Lens.

Is Your Contract Manufacturer on FDA’s Enforcement Radar? If you source APIs or finished products from Indian generics manufacturers, your supplier qualification program may not be going deep enough. FD-AID LLC conducts supplier quality assessments and data integrity gap analyses grounded in real FDA enforcement experience. Contact devaughn@fdaid.org to schedule a consultation before FDA’s next inspection cycle begins.

Read the full analysis – including the complete enforcement timeline, the specific violations FDA cited, and what your procurement and quality teams need to do now:

The Investigator’s Lens: https://devaughnedwards.substack.com/p/fda-caught-intas-pharmaceuticals

DeVaughn Edwards is a former FDA Investigator with 14 years of federal service and 13 years as a pharmaceutical quality executive. He is the founder and Principal Consultant of FD-AID LLC (fdaid.org).

devaughn@fdaid.org | devaughn@gmail.com

Copyright FDAID LLC 2026

The Cohance Lifesciences Limited Warning Letter breakdown

Most QA teams treat the 15-business-day response window as the finish line. Submit on time, check the box, move on.

Cohance Lifesciences did exactly that. Their inspection ended August 12, 2025. They submitted their 483 response September 2 – inside the window. Five months later, FDA issued Warning Letter 320-26-40.

The response was on time. It was also inadequate. And FDA said so in writing.

What the Warning Letter Actually Said

The lead observation cited 21 CFR 211.192 – failure to thoroughly investigate an unexplained discrepancy or batch failure. Cohance received complaints across multiple batches for crumbling, disintegrating, pitted tablets with dust in the bottle. Their investigation closed as “Not Substantiated.” Their investigation note attributed the issue to the inherent nature of a raw material – and then noted two additional complaint investigations showing the same problem across three other batches of the same product.

The firm reopened the investigation after the 483. Revised the root cause. Submitted their response.

FDA’s conclusion: “Your response is inadequate.”

Four separate failures documented in a single paragraph of the Warning Letter. Not four new findings – four things the response failed to say.

The Problem Is Not the Observation. It Is the Response.

There is specific language that signals to the reviewer at CDER headquarters that the firm does not understand the depth of its own problem. That language is in 483 responses far more often than most QA teams realize – because nobody teaches you what FDA is actually reading for.

The Cohance letter is a textbook example. The violations are not unusual. The investigation type is not unusual. What is unusual is how clearly the Warning Letter documents exactly what the response failed to include – making it one of the more instructive enforcement letters issued in early 2026.

The full analysis of the Cohance Warning Letter – including the exact language in 483 observations that signals a Warning Letter is already being drafted, the five-part response structure, and what Cohance should have written – is available to paid subscribers of The Investigator’s Lens.

https://open.substack.com/pub/devaughnedwards/p/the-exact-wording-on-a-483-that-tells?r=7sflcx&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

Questions about your 483 situation: devaughn@fdaid.org | fdaid.org

FDA issued a Warning Letter to Sato Pharmaceutical Co., Ltd., a Japanese OTC drug manufacturer, on May 18, 2026.

I want to be direct about what this letter actually represents before we get into the specifics. This is not a Warning Letter for inadequate procedures or incomplete documentation. This is FDA telling a manufacturer that their sterile filling line is fundamentally unsuitable for sterile manufacturing.

Those are two different categories of finding. And they have two very different trajectories.

As an FDA Investigator, I conducted sterility-related inspections. When I read language like “fundamentally unsuitable for its intended use” in a Warning Letter, I know what that means operationally. It means FDA does not believe this facility can manufacture sterile drug products safely under current conditions. Not that they need to improve. That the foundation is wrong.

Here is what FDA found:

Six Media Fill Failures Over Two Years

Between November 2022 and February 2025, Sato’s attempts to validate their aseptic filling line resulted in at least six media fill failures.

For those unfamiliar with media fill operations: it is basically a simulation of a facility’s routine production process using open containers filled with growth media that captures any microbial contamination. It gives actual evidence of what is happening during production, from personnel habits to environmental integrity.

The airflow visualization studies made the situation worse. These are smoke studies that could not demonstrate what they were designed to demonstrate.

Stability Programs That Cannot Detect Degradation

A stability program is supposed to detect product degradation over time.

Products were distributed to the U.S. market with stability data that showed unidentified impurity peaks that were never evaluated for patient safety.

Sato manufactured and released OTC drug products to the U.S. market without conducting required microbiological testing.

They may still be on U.S. pharmacy shelves.

FDA required reserve sample testing, health hazard evaluations, patient risk assessment, and evaluation of the need for market action.

The vulnerabilities FDA found at Sato Pharmaceutical are not unique to one Japanese OTC manufacturer. Aseptic process design deficiencies that produce media fill failures exist at other facilities.

The full breakdown, including what FDA is really saying behind each finding and the specific actions your quality team should take right now, is in the paid edition of The Investigator’s Lens.

Read the full article here: https://open.substack.com/pub/devaughnedwards/p/sato-pharmaceutical-just-got-an-fda?r=7sflcx&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831

I have published articles that made compliance professionals uncomfortable. Articles that named what most publications in this space are too cautious to name. Articles that generated more direct replies than anything else I have written.

This one is different.

What you are about to read is the most controversial conversation ever published in The Investigator’s Lens. Four former FDA Investigators, combined 71 years of field experience, sitting in a room and saying out loud what most people in this industry will only say in private.

The topic: why pharmaceutical companies keep getting away with repeat violations. Not the official answer. The real one.

What Makes This Conversation Different

Most discussions of FDA enforcement stay safely in the abstract. Resource constraints. Regulatory complexity. The inherent difficulty of inspecting a global supply chain with a finite workforce.

This conversation does not stay in the abstract.

One participant is a former Investigator now sitting as a VP of Quality inside a major pharmaceutical manufacturer. He described, on the record, how resource allocation decisions are actually made inside large pharmaceutical organizations when a 483 observation does not affect a high-priority product. People in his position do not say this publicly. He said it.

One participant is a PhD microbiologist with 18 years of FDA field experience who now consults on sterility assurance and contamination control. She named the specific operational decisions that create repeat contamination control failures. Not in the abstract.

One participant is a registered nurse who spent 17 years conducting FDA inspections including clinical trial site inspections. She described sitting with patients in clinical trials who experienced serious adverse events in programs where the sponsor had been cited for similar failures in a prior trial. She is the voice in this conversation that will not let the discussion stay comfortable.

And there is me. 14 years as an FDA Investigator. 13 years as a Quality executive on the industry side. 6 years auditing from the outside. I have seen this problem from every angle and I moderated this conversation because I believed it needed to exist.

We talked about the enforcement tools FDA has and is
not using. We talked about what happens inside organizations when
the connection between a CAPA response and the patient
at the end of the supply chain gets lost. And we talked about what breaks the cycle.

Read the full roundtable here: https://open.substack.com/pub/devaughnedwards/p/the-roundtable-pharmaceutical-companies?r=7sflcx&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831

Most inspection readiness programs are built around the same assumption: if your documents are in order, your CAPA system is current, and your staff is trained, you are prepared.

I went back to three of my former FDA Investigator colleagues, combined 40-plus years of field experience between them, and asked each one to describe a facility that actually impressed them during an inspection.

Not a facility that was clean. A facility that made them stop and think: these people have genuinely figured something out.

What they described was consistent across all three conversations. The same behaviors. The same signals. The same moments that told a career Investigator that this quality organization was operating at a level above what the regulations require.

None of the behaviors they described are beyond the reach of a well-managed facility. They do not require exceptional resources or a large quality team.

They require something simpler and considerably harder to manufacture on short notice: a quality culture that operates the same way whether FDA is in the building or not. And the full support of senior management.

The Five Behaviors Are in The Investigator’s Lens

This article covers all five behaviors that career FDA Investigators identified as the markers of a quality organization operating at the highest level — including what each behavior signals to a trained Investigator and exactly what your site should be doing to get there.

It is the third article in the Three Former FDA Investigators series. The most important one yet.

Read the full article here: https://open.substack.com/pub/devaughnedwards/p/d34?r=7sflcx&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831

I went back to my three former FDA Investigator colleagues for a second conversation.

The first time I asked them how they found deficiencies. This time I asked them where.

I spent 14 years as an FDA Investigator myself. Then 13 years as a Quality executive on the industry side. Then 6 years auditing from the outside. I have seen every one of these areas from every angle — as the Investigator writing the 483, as the Quality Director receiving it, and as the auditor warning companies before FDA arrived.

What my former colleagues described was not random. Across different facilities, different product types, different states — the same five areas produced the most critical findings. Every time.

Before I name them, one thing worth stating clearly: those websites that collect 483 observations and try to help companies profile Investigators based on citation patterns are not useful. Most inspections involve more than one Investigator. You don’t know which observation belongs to which person. You’re profiling a ghost.

What my colleagues described is different. This is institutional knowledge from career Investigators — the areas where deficiencies were most likely to indicate a quality system that had lost genuine control.

The ones that drove Warning Letters. The ones that resulted in OAI classifications. The ones that ended careers and shut down production lines.

And that’s not hyperbole. In one inspection, the Quality Director abruptly resigned on the second day.

Why This Intelligence Is Different

The most commonly cited 483 observations are publicly available. FDA publishes the data. What is not publicly available is what a career Investigator actually looks for within each of those systems — the specific patterns, the specific data requests, the specific interview questions that reveal whether a system is functioning or being managed for appearances.

That is what my three former colleagues shared. And it is what is in the paid edition of The Investigator’s Lens — including CFR citations for each area, the specific techniques Investigators use to evaluate each system, and the preparation actions that neutralize each vulnerability before FDA identifies it.

Read the full article here: https://open.substack.com/pub/devaughnedwards/p/former-fda-investigators-revealed?r=7sflcx&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831

This is not a proposal. It is not a pilot that is still being evaluated. It is already happening.

In a May 6, 2026 press announcement, FDA confirmed it has been conducting shorter, focused one-day inspectional assessments since April 2026. As of the announcement, approximately 46 assessments had already been completed. Facilities are being selected right now using risk-based criteria — and most Quality teams have no idea this program exists.

I spent 14 years as an FDA Investigator. When I read the language FDA used to describe this program, I want to make sure every regulated facility understands what it actually says.

What FDA Actually Said

FDA framed the 1-day assessment program as an efficiency measure. Read past that framing and focus on this specific language from the announcement:

Data gathered through these assessments — such as recurring compliance themes, facility-specific risk scores, and discrepancies between registered and actual operations — can be used to better target future oversight activities.

Discrepancies between registered and actual operations. FDA is telling you directly that one purpose of a 1-day assessment is to identify facilities operating outside their registration scope. If your site has added processes, product lines, or contract manufacturing arrangements since your last inspection — and your registration has not been updated to reflect that — you are a target.

The program covers multiple FDA inspectorates. Human and animal foods. Biologics. Medical products. Clinical research programs. This is not a drug-only initiative. If you are a regulated facility of any type, you are in scope.

Why the 1-Day Format Is More Dangerous Than a Standard Inspection

Traditional inspection preparation gives you a runway. You brief your subject matter experts. You stage your document room. You rehearse your escort team. A 1-day assessment collapses that runway to zero.

In many cases your team will not know the visit is happening until an Investigator is already in the lobby. There is no time to locate records, no time to brief anyone, no time to find the right person to answer a question. What your team does in the first 30 minutes is all there is.

And here is the detail that should concern every Quality Director reading this: assessments have extended beyond one day when significant observations were identified. A 1-day visit that becomes a multi-day investigation is the worst possible outcome. It means your facility gave the Investigator a reason to stay.

Who Gets Selected

FDA is using risk-based selection criteria. Prior inspection outcomes are a primary factor. A prior 483 observation, a Warning Letter history, or an adverse event pattern elevates your facility’s risk score. Product type and operational characteristics also factor in.

If your last inspection ended with observations that were closed on paper but not fully remediated in practice, your risk score is elevated. If your registration does not accurately reflect what your facility currently does, your risk score is elevated. If your quality system cannot produce core documentation within minutes, your risk posture will be visible the moment an Investigator walks in.

You have time right now to address all of this. Most facilities are not using it.

What Comes After a 1-Day Assessment

A 1-day assessment is not a courtesy visit. Investigators conducting these assessments have the same authority available to them as a standard inspection. Observations made during a 1-day assessment can trigger a full follow-up inspection. Risk scores generated from these visits can influence your facility’s regulatory standing for years.

The facilities that come out of these assessments cleanly are not necessarily the most technically compliant. They are the ones in a continuous state of inspection readiness — where the answer to any document request is measured in minutes, not hours, and where every person on the floor knows exactly what to do when a stranger walks in with credentials.

The Full Playbook Is in The Investigator’s Lens

How to audit your registration against actual operations. How to run a real unannounced mock assessment. What FDA Investigators focus on first in a compressed one-day visit. How to eliminate the specific conditions that trigger scope escalation.

That intelligence is in the paid edition of The Investigator’s Lens — written by former FDA Investigators who have conducted exactly the type of assessment FDA is now deploying at scale.

Read the full article here: https://devaughnedwards.substack.com/p/regulatory-alert-fdas-new-supplemental?r=7sflcx

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831